Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
4.07% $2.81
/ 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 17.90 mill |
EPS: | -0.400 |
P/E: | -7.02 |
Earnings Date: | Mar 14, 2024 |
SharesOutstanding: | 6.37 mill |
Avg Daily Volume: | 0.738 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -7.02 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -7.02 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0093 (-99.67%) $-2.80 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.76 - 2.86 ( +/- 1.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2008-11-18 | Edelman Joseph | Sell | 24 681 360 | Ordinary Shares |
2008-11-18 | Edelman Joseph | Sell | 2 696 450 | Ordinary Shares |
2008-11-19 | Edelman Joseph | Sell | 9 600 000 | Ordinary Shares |
2008-11-18 | Edelman Joseph | Sell | 29 740 | Ordinary Shares |
2008-11-18 | Edelman Joseph | Sell | 400 000 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 14 134 720 | Sell: 44 453 703 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.81 (4.07% ) |
Volume | 0.233 mill |
Avg. Vol. | 0.738 mill |
% of Avg. Vol | 31.53 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.